BSc(Hons), MBA, GAICD
Anne-Marie Birkill is a Co-Founder, Venture Partner, and Director of the Manager at OneVentures. She is well regarded for her passion for and experience of working with early-stage technology companies and entrepreneurs including as an expert advisor within the innovation community. She is based in Brisbane, a strong source of technology innovation opportunities.
Driven by a passion to grow Australia’s knowledge-based economy; Anne-Marie brings 35+ years’ experience in executive leadership, product development and commercialisation, advisory roles, mentorship, capital raising and exits to the team at OneVentures. Her expertise in spans both the technology and healthcare sectors.
A committed advocate for diversity, equity and inclusion, Anne-Marie regularly contributes to thought leadership on this topic including via speaking engagements. For media and speaking enquiries, please contact us)
Anne-Marie prioritises kindness in all she does and has a natural curiosity traversing many interests. Whether hiking remote trails, planning her latest renovation project; or cooking up a storm for family and friends, she really does nothing by halves.
Anne-Marie lives in vivid colour and is the most likely team member in the office to protest about any promotional materials being printed in grey.
Anne-Marie serves on the investment committees of OneVentures’ Funds I, II and III and the REM and Risk Management Committees.
Anne-Marie is a highly experienced executive and has board responsibilities as a Director within OneVentures portfolio companies iStaySafe and Madorra.
Anne-Marie’s interest in the innovation sector was forged during 15 years in leadership roles in agri-business companies developing and commercialising new cultivars of ornamental, aquatic, food, and forestry plants. Prior to co-founding OneVentures in 2010, she was CEO of i.lab Incubator, having previously spent five years in the senior management team at UniQuest. During this period Anne-Marie developed successful programs and networks to assist technology commercialisation, start-up formation and growth, capital raising and exit. She has experience of senior management in listed and unlisted companies and was a Director for energy storage company RedFlow Limited during its successful listing on the ASX (ASX:RFX).
Anne-Marie was Chair of the Board of Charm Health until 2017 when she lead the company to an acquisition by the Citadel Group (ASX:CGL). She originated Vaxxas in 2010 and was an observer to the Vaxxas Board until 2020.
Her experience and reputation in the technology sector is demonstrated through her active participation in the innovation community. She is currently an Industry Fellow with The University of Queensland (UQ) Business School, a director for InterFinancial Corporate Finance and a member of the Advisory Panel for the $100M Advance Queensland Business Investment Fund. She is an inaugural member of the AIC Champions of Change.
13 August 2018
BEc (Hons), MBA
Nigel Dews is an Operating Partner at OneVentures and leads the Technology team within the firm. Nigel is a digital revolutionary, having been an Executive Leader in the digital media, technology and telecommunications industries for 20+ years.
Nigel is renowned for his experience as both a strategic consultant and a proven entrepreneur. He has experience as a start-up CEO as well as a strong history within large multinationals: providing critical leadership to pivot into the digital landscape.
Nigel was born in NZ, grew up in Australia and has also lived across both the US and Europe. Wherever he is in the world though, he loves the outdoors – with a bias towards Central Otago. Whether he’s hiking, running or catching a wave with his family, Nigel rarely stops moving when he’s out of the office.
Nigel joined OneVentures to predominantly to work with our digital and technology-based portfolio businesses. He currently serves on the Investment Committee of the OneVentures Growth Fund V, advises the Fund IV team and works extensively with our portfolio companies.
Nigel is a highly experienced executive, consultant and has board responsibilities as a Director with OneVentures portfolio companies Lumary, Kepler Analytics, Flippa and SourseAI.
Nigel has been a leader in the digital media, technology and telecommunications industries as CEO of Vodafone Hutchison Australia, 3 Mobile, and the first Chief Executive of the Fairfax Media digital business. More recently, Nigel was CEO of Melbourne-based technology scale-up, Message Media, leading the strategy development and execution to rapidly grow via organic sales acceleration, acquisitions, new products and geographic expansion, attracting private equity and leading to an eventual trade sale.
Nigel initially worked at the Reserve Bank of Australia, spent five years in strategy consulting with McKinsey & Company before moving into leadership positions in the emerging category of digital media.
He built and led the start-up of Fairfax Digital for its first seven years, taking it through to break-even. He led the building of a diverse portfolio of organically grown, joint ventured and acquired digital businesses.
Nigel has held notable leadership roles including CEO of Hutchison Telecoms Australia (HTA) and 3 Mobile, leading the merger and integration of 3 with Vodafone, remaining as CEO of the merged entity for its first 3 years.
After starting-up European border mobile network enabler Hue in the UK, Nigel returned to Sydney and joined strategy consultants Port Jackson Partners as a Director and shareholder leading strategy projects across a range of industries in Australia, New Zealand, United Arab Emirates and United Kingdom. This included work with CEOs of fast growing digital businesses, digital and technology strategies, media, infrastructure, agriculture and international growth initiatives.
Nigel joined Message Media in 2017 to scale-up and transform the business from a single region, single product, single shareholder business via a substantial investment in technology, people, new processes and platforms, and acquisitions, culminating in a significant private equity investment and founder exit. He is also a founding partner of GNG Partners, a boutique growth strategy consulting firm.
BSc (Biology), MD (Rheumatology)
Dan Baker received his B.A. in Biology from Gettysburg College and his medical degree from the University of Pennsylvania. He completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the University of Pennsylvania, followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on the faculty of the University of Pennsylvania for 18 years before joining Janssen/Centocor in 2000.
As Vice President Immunology R&D at Janssen, his responsibilities included the clinical development of Remicade, SIMPONI and STELARA as well as other programs in rheumatology, and dermatology. As Disease Area Stronghold Leader he was responsible for Phase II & III clinical development plans for rheumatology products was responsible for the overall strategy on portfolio in rheumatology/immunology.
He has authored multiple publications in the field of immunology and has served a co-Lead of RTCure which is an academic/industry collaboration that is sponsored by IMI2 and is searching for tolerogenic therapies for rheumatoid arthritis.
After his retirement from Janssen in 2019 he has been active in continuing to be involved in bringing therapies to patients by providing scientific advice to drug development organisations. He has taken on the role of CEO of Kira Biotech which is an emerging Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs
Ba Speech Communication
Kelly Constable is a senior business executive offering 20 years of international commercialisation expertise in life sciences. Kelly’s expertise includes eight years leading breakthrough digital applications in precision medicine in the US and EU. She has a proven track record driving value in a top global biotech organization, through partnerships with multinational corporations and as a strategic thinker on startup Boards and teams.
Currently, Kelly is the Co-Founder and CEO of AULUS Partners, dedicated to accelerating commercialisation of high potential life sciences and med tech companies. She is the Chief Strategy Officer for Omico, a precision oncology clinical trials platform. She joined OneVentures Healthcare Fund as a part-time Venture Partner to focus on internationalising existing portfolio companies and to identify new opportunities. She serves on the Board of Directors of Prota Therapeutics, Oculo, and ANDHealth. Kelly serves as an expert advisor and commercial lead to NSW Health Gene Therapy and Manufacturing Initiative and she serves on the Investment Committee of the NSW Medical Device Fund.
Kelly developed her expertise at Abbott Labs through various roles in sales and marketing across general medicine and specialty therapeutics. Kelly joined Amgen in 2006, a world leader in biotechnology. She led the launch of the Sureclick autoinjector in 2006 and repositioned Aranesp after a FDA label change and led the US launch strategy for Prolia in osteoporosis in 2009, each >$1B annual sales products. More recently, Kelly led the global launch strategy for Aimovig in migraine through 2016.
Kelly developed her expertise in digital health and precision medicine when she was asked by Amgen to create a dedicated US innovation unit. In this role, she led and negotiated Amgen’s first technical alliance with GE Healthcare and through this strategic partnership, developed and launched the first point of care software algorithm in osteoporosis, deployed initially in the US and now globally. Next Kelly co-founded Amgen’s first precision oncology initiative as a start-up inside Amgen, developing a novel algorithm for anaemia in cancer, raising $20M of seed funding and managing Amgen’s first commercial software team with 50 cross-discipline experts in mathematics, software, biotech, regulatory, operations, and commercialisation. She oversaw the development and implementation of Amgen’s first software medical device solution in Germany which has since been launched in multiple countries across Europe. Kelly also served as the expert advisor in digital health to Amgen Ventures, the company’s Corporate Venture Fund, reviewing opportunities and participating in funding transactions.
In 2016, Kelly left corporate life after 20 years to become a full-time entrepreneur. She founded AULUS Partners with a mission to embrace start-ups that harness the potential to transform healthcare issues on a global scale. Currently AULUS is associated with four portfolio companies in the USA.